Minoo Ahmadinejad Explores Emicizumab
Minoo Ahmadinejad, Laboratory Director at Iranian Blood Transfusion Organization, shared on LinkedIn:
”Advances in hemophilia management had introduced novel therapies that challenged traditional approaches to laboratory monitoring.
Yesterday, I presented to medical doctors and specialists in hemato‑oncology on Emicizumab—a bispecific monoclonal antibody—and its impact on interpreting conventional coagulation assays.
Because standard tests such as aPTT and one-stage factor VIII activity appeared normalized.
The methods for measuring Emicizumab concentration needs modified specialized assays and measurements of FVIII activity or it’s inhibitor in the patient’s on Emicizumab treatment required chromogenic factor VIII tests with bovine reagents, for accurate assessment.
Through this discussion, I highlighted the key laboratory considerations, potential pitfalls, and strategies clinicians needed to adopt to ensure safe and effective patient care under this innovative treatment.”
Stay updated with Hemostasis Today.
-
Aug 10, 2026, 16:09Preetie Shetty Akkunje: Making Stroke Rehabilitation Accessible in Low-Resource Settings
-
Aug 10, 2026, 15:50The Next Antithrombotic Frontier: GPVI Inhibitors Beyond Aspirin
-
Aug 10, 2026, 15:47Edward Lee Carter: 61% of Patients on Reduced-Dose Apixaban Did Not Meet Label Criteria
-
Aug 10, 2026, 15:45Vrushali Lad: What Living With DVT Taught Me About Lifestyle and Movement
-
Aug 10, 2026, 15:42Wolfgang Miesbach: Cognitive Impairment in aPL-Positive Patients
-
Aug 10, 2026, 15:39Iftikhar Khan: What Is the Optimal Antithrombotic Strategy After Left Atrial Appendage Closure?
-
Aug 10, 2026, 15:36Anas Hamad: Medication Adherence and Treatment Persistence Following the Switch From VKAs to DOACs
-
Aug 10, 2026, 15:11Shazmah Shaikh: How Does a Thrombus Actually Form?
-
Aug 10, 2026, 15:01William Wallace: Is Your Cholesterol Test Missing Your Biggest Inherited Risk?